慢加急性肝衰竭患者少量腹水穿刺也可发生穿刺诱导循环功能障碍,白蛋白输注可部分改善
研究纳入80例接受<5L腹水穿刺的慢加急性肝衰竭(ACLF)患者,随机分为白蛋白组(8g/dL腹水,n=40)与无白蛋白组(n=40)。无白蛋白组穿刺诱导循环功能障碍(PICD)发生率更高(70% vs 30%,P=0.001),肝性脑病、低钠血症、急性肾损伤及院内死亡率亦更高;白蛋白输注降低第6天PICD发生率(OR 0.068,95%CI 0.011-0.43,P=0.005)。
要点
- ACLF患者即使少量腹水穿刺(<5L)也可发生PICD,无白蛋白组发生率达70%。
- 白蛋白输注(8g/dL腹水)降低第6天PICD发生率(OR 0.068,95%CI 0.011-0.43,P=0.005)。
- 无白蛋白组肝性脑病、低钠血症、急性肾损伤及院内死亡率均更高。
核心结论
- ACLF患者接受少量腹水穿刺即可发生PICD,白蛋白输注可降低PICD发生率及死亡率。
研究设计与样本
- 随机对照试验,纳入80例接受<5L腹水穿刺的ACLF患者,白蛋白组(8g/dL腹水,n=40)与无白蛋白组(n=40)。
- 序贯随访检测PICD,基线特征组间可比,包括腹水穿刺量(4.16±0.23 vs 4.14±0.27 L,P=0.72)和血浆肾素活性(PRA;20.5±7.03 vs 23.2±8.24 ng/mL/hour,P=0.12)。
主要发现
- 无白蛋白组PICD发生率高于白蛋白组(70% vs 30%,P=0.001)。
- 无白蛋白组肝性脑病发生率更高(50% vs 27.5%,P=0.04)。
- 无白蛋白组低钠血症发生率更高(67.5% vs 22.5%,P<0.001)。
- 无白蛋白组急性肾损伤发生率更高(62.5% vs 30%,P=0.001)。
- 无白蛋白组院内死亡率更高(62.5% vs 27.5%,P=0.003)。
关键数值与推荐
- 第3天PRA 25.15 ng/mL预测第6天发生PICD的敏感度71%、特异度68%。
- 白蛋白输注降低第6天PICD发生率(OR 0.068,95%CI 0.011-0.43,P=0.005)。
临床怎么用
- ACLF患者行少量腹水穿刺时应警惕PICD发生,可考虑输注白蛋白(8g/dL腹水)以降低PICD及死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Paracentesis-induced circulatory dysfunction (PICD) is a serious complication of large-volume (>5 L) paracentesis in cirrhosis and is reduced with albumin infusion. There is a lack of data on PICD in acute-on-chronic liver failure (ACLF). Because ACLF patients have greater hemodynamic derangements than patients with decompensated cirrhosis, we investigated whether PICD could develop with modest-volume paracentesis (MVP) and the role of albumin infusion. APPROACH AND RESULTS: A total of 80 ACLF patients undergoing <5 L paracentesis were randomized to receive albumin (8 g/dL of ascitic fluid; n = 40) or no albumin (n = 40) and serially followed to detect PICD. Baseline characteristics were comparable between groups, including volume of ascitic tap (4.16 ± 0.23 versus 4.14 ± 0.27 L; P = 0.72) and plasma renin activity (PRA; 20.5 ± 7.03 versus 23.2 ± 8.24 ng/mL/hour; P = 0.12). PICD was more frequent in the no-albumin group than the albumin group (70% versus 30%; P = 0.001), with higher incidence of hepatic encephalopathy (50% versus 27.5%; P = 0.04), hyponatremia (67.5% versus 22.5%; P < 0.001), acute kidney injury (62.5% versus 30%; P = 0.001), and in-house mortality (62.5% versus 27.5%; P = 0.003). PRA of 25.15 ng/mL at day 3 had sensitivity and specificity of 71% and 68%, respectively, for development of PICD at day 6. Albumin infusion decreased the incidence of PICD at day 6 (odds ratio, 0.068; 95% confidence interval, 0.011-0.43; P = 0.005). CONCLUSIONS: PICD is common and develops even with MVP in ACLF patients. Albumin infusion decreases the incidence of PICD and mortality in patients with ACLF. Clinical trial identifier: NCT02467348.
引用
- Arora V, Vijayaraghavan R, Maiwall R, et al. Paracentesis-Induced Circulatory Dysfunction With Modest-Volume Paracentesis Is Partly Ameliorated by Albumin Infusion in Acute-on-Chronic Liver Failure. Hepatology. 2020. PMID: 31849085. doi:10.1002/hep.31071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。